Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry-Reference-Cited by-同舟云学术

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Published:2013-08-15 Issue:7 Volume:122 Page:1284-1292
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Höglund Martin¹,Sandin Fredrik²,Hellström Karin²,Björeman Mats³,Björkholm Magnus⁴,Brune Mats⁵,Dreimane Arta⁶,Ekblom Marja⁷,Lehmann Sören⁴,Ljungman Per⁴,Malm Claes⁶,Markevärn Berit⁸,Myhr-Eriksson Kristina⁹,Ohm Lotta⁴,Olsson-Strömberg Ulla¹,Själander Anders¹⁰,Wadenvik Hans⁵,Simonsson Bengt¹,Stenke Leif⁴,Richter Johan⁷

Affiliation:

1. Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden;

2. Regional Cancer Centre, Uppsala-Örebro, Sweden;

3. Department of Hematology, University Hospital, Örebro, Sweden;

4. Department of Hematology, Karolinska University Hospital and Department of Medicine, Karolinska Institutet, Stockholm, Sweden;

5. Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden;

6. Department of Hematology, University Hospital, Linköping, Sweden;

7. Department of Hematology and Coagulation, Skåne University Hospital, Lund, Sweden;

8. Department of Hematology, University Hospital, Umeå, Sweden;

9. Department of Hematology, Sunderby-Luleå Hospital, Luleå, Sweden; and

10. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

Abstract

Key Points Patients up to age 70 years with CML treated within a decentralized health care setting had a relative survival close to 1.0. Sokal, but not EUTOS, score at diagnosis predicted overall and relative survival in a population-based cohort of patients with CML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/7/1284/1373256/1284.pdf

Reference38 articles.

1. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.;Kantarjian;Blood,2012

2. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa.;Hasford;J Natl Cancer Inst,1998

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients;Biomedicines;2023-09-07

2. Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐dependence, minimizing undesirable drug–drug interactions;European Journal of Haematology;2023-07-28

3. Sex‐specific incidence of hepatitis B virus flares among Bcr‐Abl tyrosine kinase inhibitor users in Taiwan;Pharmacoepidemiology and Drug Safety;2023-07-18

4. Biochemical and breakpoint cluster region-c-ABL oncogene 1 polymorphism study among Iraqi patients with chronic myeloid leukemia;Iraqi Journal of Hematology;2023

5. Chronic Myeloid Leukemia: who should get a treatment-free trial and how?;Canadian Hematology Today;2022-11-01